Cargando…
Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422947/ https://www.ncbi.nlm.nih.gov/pubmed/34504494 http://dx.doi.org/10.3389/fimmu.2021.712351 |
_version_ | 1783749375294439424 |
---|---|
author | Liu, Gang Zhou, Wenxuan Li, Xiaoli Guo, Lijie He, Tingting Zhao, Juan Gong, Liansheng |
author_facet | Liu, Gang Zhou, Wenxuan Li, Xiaoli Guo, Lijie He, Tingting Zhao, Juan Gong, Liansheng |
author_sort | Liu, Gang |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are commonly administered for HCC as combination therapy, including combined anti-angiogenic and immunotherapy combination therapy. We report a case of a primary massive HCC patient with portal hepatic vein tumor thrombus who had a good response to atezolizumab in combination with bevacizumab, following progression of disease on combined immunotherapy with pembrolizumab and lenvatinib. This case demonstrates for the first time that an HCC patient who is resistant to anti-PD-1 antibody immunotherapy can benefit from anti-PD-L1 antibody immunotherapy, providing a potentially promising strategy for the treatment of HCC. |
format | Online Article Text |
id | pubmed-8422947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84229472021-09-08 Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody Liu, Gang Zhou, Wenxuan Li, Xiaoli Guo, Lijie He, Tingting Zhao, Juan Gong, Liansheng Front Immunol Immunology Hepatocellular carcinoma (HCC) is an aggressive liver tumor that occurs due to chronic liver disease, and it has a high mortality rate and limited treatment options. Immune checkpoint inhibitors have been successfully introduced and used in cancer therapy, among which inhibitors of programmed death ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are commonly administered for HCC as combination therapy, including combined anti-angiogenic and immunotherapy combination therapy. We report a case of a primary massive HCC patient with portal hepatic vein tumor thrombus who had a good response to atezolizumab in combination with bevacizumab, following progression of disease on combined immunotherapy with pembrolizumab and lenvatinib. This case demonstrates for the first time that an HCC patient who is resistant to anti-PD-1 antibody immunotherapy can benefit from anti-PD-L1 antibody immunotherapy, providing a potentially promising strategy for the treatment of HCC. Frontiers Media S.A. 2021-08-24 /pmc/articles/PMC8422947/ /pubmed/34504494 http://dx.doi.org/10.3389/fimmu.2021.712351 Text en Copyright © 2021 Liu, Zhou, Li, Guo, He, Zhao and Gong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Liu, Gang Zhou, Wenxuan Li, Xiaoli Guo, Lijie He, Tingting Zhao, Juan Gong, Liansheng Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody |
title | Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody |
title_full | Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody |
title_fullStr | Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody |
title_full_unstemmed | Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody |
title_short | Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody |
title_sort | case report: complete response of primary massive hepatocellular carcinoma to anti-programmed death ligand-1 antibody following progression on anti-programmed death-1 antibody |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422947/ https://www.ncbi.nlm.nih.gov/pubmed/34504494 http://dx.doi.org/10.3389/fimmu.2021.712351 |
work_keys_str_mv | AT liugang casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody AT zhouwenxuan casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody AT lixiaoli casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody AT guolijie casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody AT hetingting casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody AT zhaojuan casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody AT gongliansheng casereportcompleteresponseofprimarymassivehepatocellularcarcinomatoantiprogrammeddeathligand1antibodyfollowingprogressiononantiprogrammeddeath1antibody |